RPRichard J. Perrin

Richard J. Perrin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Richard J. Perrin has a total of 678 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploring healthy aging through preclinical Alzheimer disease in the Knight Alzheimer Research Imaging dataset

    by David A. Hoagey, Nicole S. McKay, Nelly Joseph-Mathurin, Shaney Flores, Stephanie Doering, Sarah J. Keefe, Savannah Tiemann Powles, Russ C. Hornbeck, Thomas H. Smith, Jalen Scott, et al.

    Alzheimer disease (AD) remains a significant global public health challenge, requiring robust multimodal datasets to elucidate its prolonged preclinical phase, improve early detection, advance understanding of disease trajectories, and guide intervention strategies. Here we present the Knight Alzheimer Research Imaging (KARI) dataset, established by the Washington University Knight ADRC to address this critical need. We detail comprehensive multimodal neuroimaging from 1,645 participants (aged 42-97) across 6,217 acquisitions. Spanning the AD spectrum from healthy aging to symptomatic disease, the cohort undergoes extensive longitudinal imaging using structural and functional magnetic resonance imaging (MRI) alongside positron emission tomography (PET) tracers for amyloid and tau pathology. This is complemented by rich clinical, cognitive, genetic, and biomarker data. In addition to raw imaging, the dataset provides quality-controlled processed outputs, including anatomical segmentations and biomarker quantification. By making this data accessible to researchers, the Knight ADRC aims to accelerate discoveries in pathophysiology, biomarker identification, and therapeutic development.

  • Open Access

    Priming of CD8+ T cells by peripheral dendritic cells exacerbates tau-mediated neurodegeneration

    by Hao Hu, Peter Bor-Chian Lin, Carisa Zeng, Yongyi Li, Megan E. Bosch, Joshua T. Emmerson, Prabal Sharma, Ray A. Ohara, Wendy Dong, Tong Wu, et al.

    Alzheimer’s disease and primary tauopathies are marked by changes in adaptive immunity, with increased brain CD8+ T cells correlating with tau pathology severity. However, how peripheral T cells get primed to enter the brain and contribute to tau-mediated neurodegeneration remains unclear. In different disease conditions, conventional type 1 dendritic cells (cDC1s) cross-present antigens to prime CD8+ T cells into effector cells. We show that tauopathy mice lacking cDC1s or antigen cross-presentation are protected from neurodegeneration, with reduced brain CD8+ T cell infiltration and glial activation. The remaining CD8+ T cells exhibit limited clonal expansion, consistent with impaired priming. We further demonstrate that brain-derived antigens are presented in secondary lymphoid tissues, suggesting a site of T cell activation. Together, these findings establish cDC1-dependent peripheral priming as a key driver of CD8+ T cell accumulation in the brain and tau-mediated neurodegeneration.


  • Author Correction: A route for cerebrospinal fluid flow through leptomeningeal arterial–venous overlaps enables macromolecule and fluid shunting

    by Benjamin A. Plog, Kyungdeok Kim, Daan Verhaege, Min Woo Kim, Zachary Papadopoulos, Krikor Dikranian, Taitea Dykstra, Jay Cao, Richard J. Perrin, Katherine E. Schwetye, et al.

  • Open Access

    Blood-based circular RNAs for early diagnosis of Alzheimer’s disease

    by Bridget Phillips, Jessie Sanford, Vaibhav A. Janve, Menghan Liu, Matt Johnson, Katherine Gong, Kristy Bergmann, Joseph Lowery, Allison Flynn, William Brock, et al.

    Detection of Alzheimer's disease (AD) before the development of clinical symptoms is critical for enabling the use of new treatments. Circular RNAs (circRNAs) are highly stable non-coding RNAs enriched in the brain that can cross the blood-brain barrier. Here, analyzing blood data from 1,221 individuals with AD and healthy individuals, we identified 34 circRNAs associated with AD status. A predictive model including these 34 circRNAs was comparable to plasma phosphorylated Tau-217 (pTau217) in classifying AD based on biomarker-confirmed (amyloid-β and Tau) status and replicated in independent samples from the Knight-Alzheimer Disease Research Center (n = 551: 76 AD, 475 cognitively unimpaired) and preclinical A4 (n = 1,767) cohorts. Classification of biomarker-confirmed status by blood circRNAs (area under the curve (AUC) = 0.945) had a higher predictive ability than plasma pTau217 (AUC = 0.877) and was further improved in the integrated model (circRNA+pTau217 AUC = 0.977). This model showed high AD specificity with low predictive power for Parkinson's disease, frontotemporal dementia, and other neurodegenerative diseases. In the Knight-Alzheimer Disease Research Center discovery cohort, these circRNAs (hazard ratio = 2.92) outperformed pTau217 (hazard ratio = 1.81) and amyloid-positron emission tomography when predicting progression to symptomatic AD. Although prospective validation in larger cohorts is needed, these results propose blood circRNAs as potential biomarkers for AD diagnosis and disease progression.


  • Open Access

    Effect of Cognitive Reserve on Age at Symptom Onset and Cognitive Decline in Individuals With Dominantly Inherited Alzheimer Disease

    by Jorge J. Llibre-Guerra, Ruijin Lu, Ma. Florencia Clarens, Ian Liu, Alan Renton, Natalie S. Ryan, Alison M. Goate, David Aguillón, Ricardo Francisco Allegri, Tammie L.S. Benzinger, et al.

    Cognitive reserve has been shown to modulate the onset and progression of Alzheimer disease (AD) symptoms. Although its role in sporadic AD is well-studied, how cognitive reserve influences the timing and progression of symptoms in dominantly inherited AD (DIAD) remains unclear. This study aimed to quantify cognitive reserve in DIAD carriers and test whether higher cognitive reserve is associated with later symptom onset and slower functional decline. We analyzed data from the Dominantly Inherited Alzheimer's Network study. Cognitive reserve was modeled using a residual-based latent variable approach, decomposing cognitive performance into demographic (CogD), biomarker (CogB), and reserve or residual (CogR) components. Primary outcomes were age at clinical symptom onset (CDR >0) and longitudinal change in the Clinical Dementia Rating-Sum of Boxes (CDR-SBs). Data were analyzed using Cox proportional hazards models and linear mixed-effects models, adjusting for estimated years from onset (EYO). A total of 710 Dominantly Inherited Alzheimer Network (DIAN) participants were included in the analysis, comprising 271 non-DIAD carriers (nMC), 284 asymptomatic DIAD carriers (aMC), and 155 symptomatic DIAD carriers. In asymptomatic carriers, using a zero-inflation model adjusted for EYO showed that a 1 SD increase in the reserve component (CogR) was associated with a 4.06-fold increase in the odds of being clinically unimpaired (CDR-SB = 0; 95% CI 1.84-8.95). Similarly, a 1 SD increase in the demographic (CogD) and biomarker (CogB) components increased the odds of being CDR-SB = 0 by 2.60 (95% CI 1.10-6.16) and 5.16 (95% CI 2.00-13.33), respectively. Among symptomatic carriers, only the reserve and the biomarker components were significant. A 1 SD increase in CogR was associated with a 0.81-fold reduction in baseline CDR-SB score (95% CI 0.72-0.92), and a 1 SD increase in CogB was associated with a 0.60-fold reduction in CDR-SB (95% CI 0.50-0.71). Our findings indicate that higher cognitive reserve values are associated with delayed conversion to mild cognitive impairment and slower progression on clinical dementia rating scales. These findings suggest that cognitive reserve plays a protective role in modifying the clinical trajectory of genetically determined AD.

  • Open Access

    Blood-Based Circular RNAs Enable Early and Accurate Alzheimer’s Disease Diagnosis

    by Carlos Cruchaga, Bridget Phillips, Jessie Sanford, Menghan Liu, Matthew Johnson, Katherine Gong, Kristy Bergmann, Joseph Lowery, Allison Flynn, William Brock, et al.

    Detection of Alzheimer’s disease (AD) prior to the development of clinical symptoms is critical due to new treatments for symptomatic AD. Circular RNAs (circRNAs) are highly stable non-coding RNAs enriched in brain that can cross the blood-brain-barrier and are associated with AD. Using two large and independent whole-blood transcriptomic datasets, we identified 34 circRNAs associated with clinical AD status. A single-cutoff predictive model including these 34 circRNAs was comparable to plasma pTau217 in classifying AD based on clinical or AT status, that replicated in the independent dataset. The circRNAs (Hazard Ratio (HR): 2.92) outperformed pTau217 (HR: 1.81) and amyloid-PET when predicting progression to symptomatic AD. CircRNA levels began diverging 4–8 years before symptom onset, enabling preclinical risk stratification. The circRNA model was specific for AD showing low predictive power for PD, DLB, and FTD. These results establish blood circRNAs as robust biomarkers in AD diagnosis and disease progression.

  • Open Access

    Longitudinal brain morphometry in Parkinson's disease clinical subtypes: Distinct signatures forecast behavioral change within subtypes

    by Abdulmunaim M. Eid, Sarah Grossen, Aaron Tanenbaum, Helen Hwang, Therese V. Cash, Erin E. Franklin, Baijayanta Maiti, Erin R. Foster, Christina N. Lessov-Schlaggar, Richard J. Perrin, et al.


  • Open Access

    The Knight Alzheimer Research Imaging (KARI) dataset: a comprehensive multimodal resource for exploring aging, preclinical, and symptomatic Alzheimer disease pathology

    by Tammie Benzinger, David Hoagey, Nicole McKay, Nelly Joseph-Mathurin, Shaney Flores, Stephanie Doering, Russ Hornbeck, Thomas Smith, Jalen Scott, Gengsheng Chen, et al.

    Alzheimer disease (AD) remains a significant global public health challenge, requiring robust multimodal datasets to elucidate its prolonged preclinical phase, improve early detection, advance understanding of disease trajectories, and guide intervention strategies. To address this, the Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC) at Washington University in St. Louis established the Knight Alzheimer Research Imaging (KARI) dataset. This paper characterizes this dataset emphasizing its phenotypical depth and longitudinal scope, detailing comprehensive multimodal neuroimaging from 1,645 participants (aged 42-97) across 6,217 acquisitions. Spanning the AD spectrum from healthy aging to symptomatic disease, the cohort undergoes extensive longitudinal imaging using structural and functional magnetic resonance imaging (MRI) alongside positron emission tomography (PET) tracers for amyloid and tau pathology. This is complemented by rich clinical, cognitive, genetic, and biomarker data. In addition to raw imaging, the dataset provides quality-controlled processed outputs, including anatomical segmentations and biomarker quantification. By making this data accessible to researchers, the Knight ADRC aims to accelerate discoveries in pathophysiology, biomarker identification, and therapeutic development.


  • Systematic analysis of cellular cross-talk reveals a role for SEMA6D-TREM2 regulating microglial function in Alzheimer’s disease

    by Ricardo D’OLiveira Albanus, Gina M. Finan, Logan Brase, Nicholas Sweeney, Tae Yeon Kim, Shuo Chen, Yeonsu Ryoo, Joseph Park, Qi Guo, Abhirami K. Iyer, et al.

    Cellular cross-talk, mediated by membrane receptors and their ligands, is crucial for brain homeostasis and can contribute to neurodegenerative diseases such as Alzheimer’s disease (AD). To find cross-talk dysregulations involved in AD, we reconstructed cross-talk networks from single-nucleus transcriptional profiles of 67 clinically and neuropathologically well-characterized controls and AD brain donors from the Knight Alzheimer Disease Research Center and the Dominantly Inherited Alzheimer Network cohorts. We predicted a role for TREM2 and additional AD risk genes mediating neuron-microglia cross-talk in AD. We identified a gene network mediating neuron-microglia cross-talk through TREM2 and neuronal SEMA6D, which we predicted is disrupted in late AD stages. Using spatial transcriptomics on the human brain, we observed that the SEMA6D-TREM2 cross-talk gene network is activated near Aβ plaques and SEMA6D-expressing cells. Using tissue immunostaining of human brains, we found that SEMA6D colocalizes with Aβ plaques and TREM2-activated microglia. In addition, we found that plaque-proximal SEMA6D abundance decreased with the disease stage, which correlated with a reduction in microglial activation near plaques. These findings suggest that the loss of SEMA6D signaling impairs microglial activation and Αβ clearance. To validate this hypothesis, we leveraged TREM2 knockout human induced pluripotent stem cell–derived microglia and observed that SEMA6D induces microglial activation and Aβ plaque phagocytosis in a TREM2-dependent manner. In summary, we demonstrate that characterizing cellular cross-talk networks can yield insights into AD biology, provide additional context to understand AD genetic risk, and find previously unknown therapeutic targets and pathways.


  • Open Access

    Early Syndecan-4 Upregulation Predicts Cognitive and Pathological Trajectories in Alzheimer Disease

    by Rawan Tarawneh, Krista L. Moulder, Danai G. Topouza, Amrita Kar, Heng (Tony) Qian, Vernon S. Pankratz, Jigyasha Timsina, Erin E. Franklin, Suzanne E. Schindler, Richard J. Perrin, et al.

    Objective: Brain endothelial dysfunction is an early pathological feature of Alzheimer disease (AD). Syndecan-4 (SDC4) is a heparan sulfate proteoglycan which is an important component of the brain endothelial glycocalyx. In this study, we investigate SDC4 associations with amyloid and tau pathologies and cognitive impairment in a large longitudinal cohort of AD, including preclinical AD, and controls. Methods: The study included n =1,041 ( n =802 cognitively unimpaired and n =239 cognitively impaired) participants. Biological classification using the National Institute of Aging-Alzheimer’s Association “ATN” framework was performed in all participants. Cognitive assessments included the Clinical Dementia Rating ® -sum of boxes and the Knight-Preclinical Alzheimer’s Cognitive Composite which includes episodic memory, language, and executive function scores. Cerebrospinal fluid (CSF) total tau, p-tau181, and Aβ42/Aβ40 levels were measured using Lumipulse assays. CSF measures of SDC4 and established AD biomarkers were obtained using the Explore HT Olink Proteomics platform. Amyloid-PET ( n =719) and tau-PET ( n =302) scans were performed in subsets of participants. Partial correlations and linear mixed models, respectively, examined cross-sectional and longitudinal associations of CSF SDC4 levels with amyloid-PET and tau-PET burden and cognition adjusting for co-variates. CSF biomarker trajectories across the course of AD progression were estimated using pseudo-time models. Results: CSF SDC4 levels were elevated in AD, including the earliest preclinical stages, compared to controls and were closely associated with CSF and imaging biomarkers of amyloid and tau, and CSF biomarkers of neuronal and synaptic injury, astrocytic reactivity and microglial dysregulation. Higher CSF SDC4 levels correlated with higher global and regional amyloid-PET and tau-PET burden and worse baseline cognition. Higher baseline CSF SDC4 levels predicted more rapid progression of brain amyloid and tau, and faster decline in global cognition, episodic memory, language, and executive functions over a mean follow-up period of 8 years. SDC4 associations with cognition were mainly mediated by global tau-PET burden. Importantly, our pseudo-time models estimate that SDC4 upregulation begins very early in AD pathogenesis near the point of amyloid-positivity and increases more robustly following the point of tau-positivity. In our cohort, SDC4 was among the top 10 most important proteins (of >5,000 examined proteins) in predicting the pseudo-time models of AD progression and predicted these models to a potentially better extent than established AD biomarkers. Interpretation: Findings from this large translational longitudinal study suggest close associations of SDC4 upregulation with the progression of brain amyloid and tau pathologies in AD including the early preclinical stages. Further, we here demonstrate the ability of early increases in CSF SDC4 levels to predict trajectories of future cognitive decline over a mean follow-up period of 8 years. Therefore, we propose that SDC4 upregulation, as a potential surrogate of brain endothelial dysfunction, is an early event in AD pathogenesis which can reliably predict cognitive and pathological disease trajectories.